GlycoMimetics data reaffirm Sickle Cell opportunity, says Capital One

Capital One reiterates an Overweight rating and $12 price target on GlycoMimetics shares after the company announced that initial data from its Sickle Cell program supports the use of GMI-1687 as a point-of-care drug for patients experiencing a pain crisis as a result of SCD. The firm believes that the data confirming the safety and pharmacokinetics of GMI-1687 is “ideal for continued partnership discussions” and reaffirms the company’s opportunity in Sickle Cell, the analyst tells investors.